The acquisition marks
In
Contact:
Investor
W1S 2HR
Tel: +44 (0) 20 7399 2760
Fax: +44 (0) 20 7399 2761
Email: investors@hikma.uk.com
(C) 2022 Electronic News Publishing, source
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,939 GBX | +0.73% | +6.54% | +8.33% |
Apr. 26 | HIKMA PHARMACEUTICALS : Hikma’s Q1 progress appreciated by the markets | |
Apr. 25 | Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024 | CI |
The acquisition marks
In
Contact:
Investor
W1S 2HR
Tel: +44 (0) 20 7399 2760
Fax: +44 (0) 20 7399 2761
Email: investors@hikma.uk.com
(C) 2022 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
+8.33% | 5.34B | |
+29.68% | 681B | |
+21.30% | 556B | |
-4.35% | 361B | |
+17.65% | 325B | |
+3.77% | 285B | |
+13.70% | 235B | |
+4.52% | 199B | |
-12.15% | 189B | |
-3.79% | 157B |